

WEST Search History

DATE: Thursday, May 03, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L4	(peripheral or neuronal) and L3	20
<input type="checkbox"/>	L3	(composition or therapeutic) same L2	27
<input type="checkbox"/>	L2	serotonin same L1	250
<input type="checkbox"/>	L1	(tryptophan with hydroxylase)	483

END OF SEARCH HISTORY

=> index bioscience medicine

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:32:44 ON 03 MAY 2007

70 FILES IN THE FILE LIST IN STNINDEX

=> S (tryptophan (w) hydroxylase)

11 FILE ADISCTI
19 FILE AGRICOLA
8 FILE ANABSTR
3 FILE AQUALINE
23 FILE AQUASCI
39 FILE BIOENG
2213 FILE BIOSIS
27 FILE BIOTECHABS
27 FILE BIOTECHDS
278 FILE BIOTECHNO
67 FILE CABA
1845 FILE CAPLUS
3 FILE CEABA-VTB
1 FILE CIN
75 FILE CONFSCI
100 FILE DDFB
100 FILE DDFU
146 FILE DGENE
78 FILE DISSABS
100 FILE DRUGB
131 FILE DRUGU
20 FILE EMBAL
1804 FILE EMBASE
590 FILE ESBIODBASE
1 FILE FROSTI
33 FILES SEARCHED...
278 FILE GENBANK
1 FILE HEALSAFE
45 FILE IFIPAT
535 FILE LIFESCI
1756 FILE MEDLINE
7 FILE NTIS
8 FILE OCEAN
612 FILE PASCAL
3 FILE PHAR
50 FILES SEARCHED...
7 FILE PROMT
1 FILE PROUSDDR
1675 FILE SCISEARCH
961 FILE TOXCENTER
302 FILE USPATFULL
38 FILE USPAT2
3 FILE WATER
45 FILE WPIDS
2 FILE WPIFV
45 FILE WPINDEX
3 FILE IPA
8 FILE NAPRALERT
3 FILE NLDB

47 FILES HAVE ONE OR MORE ANSWERS, 70 FILES SEARCHED IN STNINDEX

L1 QUE (TRYPTOPHAN (W) HYDROXYLASE)

=> d rank

F1 2213 BIOSIS
F2 1845 CAPLUS

F3 1804 EMBASE
 F4 1756 MEDLINE
 F5 1675 SCISEARCH
 F6 961 TOXCENTER
 F7 612 PASCAL
 F8 590 ESBIODBASE
 F9 535 LIFESCI
 F10 302 USPATFULL
 F11 278 BIOTECHNO
 F12 278 GENBANK
 F13 146 DGENE
 F14 131 DRUGU
 F15 100 DDFB
 F16 100 DDFU
 F17 100 DRUGB
 F18 78 DISSABS
 F19 75 CONFSCI
 F20 67 CABA

=> file fl-fl1

FILE 'BIOSIS' ENTERED AT 12:35:14 ON 03 MAY 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:35:14 ON 03 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:35:14 ON 03 MAY 2007
 Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:35:14 ON 03 MAY 2007

FILE 'SCISEARCH' ENTERED AT 12:35:14 ON 03 MAY 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 12:35:14 ON 03 MAY 2007
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 12:35:14 ON 03 MAY 2007
 Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'ESBIODBASE' ENTERED AT 12:35:14 ON 03 MAY 2007
 COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 12:35:14 ON 03 MAY 2007
 COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 12:35:14 ON 03 MAY 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 12:35:14 ON 03 MAY 2007
 COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s L1

L2 12571 L1

=> S (serotonin or (serotonin (w) metabolism))(s) L2
 L3 4288 (SEROTONIN OR (SEROTONIN (W) METABOLISM))(S) L2

=> S peripheral or neuronal)(s) L3
 UNMATCHED RIGHT PARENTHESIS 'NEURONAL)(S'
 The number of right parentheses in a query must be equal to the
 number of left parentheses.

=> S (peripheral or neuronal)(s) L3

L4 338 (PERIPHERAL OR NEURONAL)(S) L3

=> s (composition or therapeutic)(s) L4

L5 4 (COMPOSITION OR THERAPEUTIC)(S) L4

=> s (composition or therapeutic) and L4

L6 61 (COMPOSITION OR THERAPEUTIC) AND L4

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 59 DUP REM L6 (2 DUPLICATES REMOVED)

=> dup rem l5

PROCESSING COMPLETED FOR L5

L8 4 DUP REM L5 (0 DUPLICATES REMOVED)

=> d ibib abs l8 1-4

L8 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2006:301114 USPATFULL <<LOGINID::20070503>>

TITLE: Enhanced indoleamine and catecholamine bio-availability

via catechin inhibition of L-Dopa decarboxylase

INVENTOR(S): Bulka, Yochanan R., Lakewood, NJ, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006257469 A1 20061116

APPLICATION INFO.: US 2006-398252 A1 20060405 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2005-594406P 20050405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: LIFE SCIENCE LABORATORIES, INC., 170 N. OBERLIN AVE,
UNIT 26, LAKEWOOD, NJ, 08701, US

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB . It is the embodiment of this invention to form novel compositions of
Indoleamines e.g. 5-Hydroxytryptophan (5HTP) and/or Catecholamines e.g.
L-Dopa with the gallo catechins e.g. (-)epigallocatechin3-O-gallate
(EGCG) and/or (-) epigallocatechin (EGC) or any of the catechins found
in green tea in a pharmaceutical or nutritional dosage or dietary
regimen be it in tablet, liquid, capsule, injectable or any other
ingestible form to achieve enhanced bioavailability and a superior
safety profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2006:247719 USPATFULL <<LOGINID::20070503>>

TITLE: Compositions and methods for neural cell production and
stabilization

INVENTOR(S): Mitalipova, Maisam, Athens, GA, UNITED STATES

Lyons, Ian, Buffalo, NY, UNITED STATES

Condie, Brian G, Athens, GA, UNITED STATES

Robins, Allan J, Athens, GA, UNITED STATES

Noggle, Scott Allen, New York, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006211111 A1 20060921

APPLICATION INFO.: US 2003-539951 A1 20031218 (10)

WO 2003-US40762 20031218

20060205 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-60434786 20021218
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Sutherland, Asbill & Brennan/Atta: Bill Warren, 999
Peachtree Street, NE, Atlanta, GA, 30309-3996, US
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 1165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for mammalian neural cell production, their stabilization and their proliferation. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a cell line or in cell culture and further contacting the cells with MEDII conditioned medium for the generation of stable mammalian neural cells from pluripotent mammalian stem cells. The invention further provides methods for the stabilization of a neural cell in culture comprising contacting the neural cell with MEDII conditioned medium. Preferably, the stabilized neural cell is a neural progenitor cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2006:144092 USPATFULL <<LOGINID::20070503>> ✓
TITLE: Compositions and methods for neural differentiation of
embryonic stem cells
INVENTOR(S): Schulz, Thomas, Athens, GA, UNITED STATES
Stice, Steven L., Athens, GA, UNITED STATES
Condie, Brian G., Athens, GA, UNITED STATES
Davidson, Bruce, Adelaide, AUSTRALIA

NUMBER KIND DATE

PATENT INFORMATION: US 2006121607 A1 20060608
APPLICATION INFO.: US 2003-524157 A1 20030808 (10)
WO 2003-US24864 20030808
20050822 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-60401968 20020808
US 2003-60459090 20030331
AU 2003-300552 20030509
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUTHERLAND ASBILL & BRENNAN LLP, 999 PEACHTREE STREET,
N.E., ATLANTA, GA, 30309, US
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2813

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent and multipotent human stem cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2005:298989 USPATFULL <<LOGINID::20070503>>
TITLE: Neural proteins as biomarkers for nervous system injury
and other neural disorders
INVENTOR(S): Wang, Kevin Ka-Wang, Gainesville, FL, UNITED STATES
Hayes, Ronald, Gainesville, FL, UNITED STATES
Liu, Ming Chen, Gainesville, FL, UNITED STATES
Oli, Monika, Gainesville, FL, UNITED STATES
PATENT ASSIGNEE(S): UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.,

GAINESVILLE, FL, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005260654 A1 20051124
APPLICATION INFO.: US 2005-107248 A1 20050415 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2004-562944P 20040415 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL,
33402-3188, US
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 4268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention identifies biomarkers that are diagnostic of nerve
cell injury and/or neuronal disorders. Detection of different biomarkers
of the invention are also diagnostic of the degree of severity of nerve
injury, the cell(s) involved in the injury, and the subcellular
localization of the injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs l7 1-59

L7 ANSWER 1 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2007:69302 USPATFULL <<LOGINID::20070503>>
TITLE: Superoxide dismutase mimics for the treatment of optic
nerve and retinal damage
INVENTOR(S): Klimko, Peter G., Fort Worth, TX, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2007060557 A1 20070315
APPLICATION INFO.: US 2004-575911 A1 20041130 (10)
WO 2004-US39830 20041130
20060414 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2003-528830P 20031211 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Alcon Research, 6201 South Freeway, Mail Code Q 148,
Fort Worth, TX, 76134, US
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for preventing and treating damage to the optic nerve and/or
retina by the use of SOD mimics, particularly pentaazacycle Mn.sup.(II)
complex SOD mimics, are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2006:301114 USPATFULL <<LOGINID::20070503>>
TITLE: Enhanced indoleamine and catecholamine bio-availability
via catechin inhibition of L-Dopa decarboxylase
INVENTOR(S): Bulka, Yochanan R., Lakewood, NJ, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006257469 A1 20061116
APPLICATION INFO.: US 2006-398252 A1 20060405 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2005-594406P 20050405 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LIFE SCIENCE LABORATORIES, INC., 170 N. OBERLIN AVE,
UNIT 26, LAKEWOOD, NJ, 08701, US
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It is the embodiment of this invention to form novel compositions of
Indoleamines e.g. 5-Hydroxytryptophan (5HTP) and/or Catecholamines e.g.
L-Dopa with the gallo catechins e.g. (-)epigallocatechin3-O-gallate
(EGCG) and/or (-) epigallocatechin (EGC) or any of the catechins found
in green tea in a pharmaceutical or nutritional dosage or dietary
regimen be it in tablet, liquid, capsule, injectable or any other
ingestible form to achieve enhanced bioavailability and a superior
safety profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2006:282139 USPATFULL <<LOGINID::20070503>>
TITLE: Modulating vesicular monoamine transporter trafficking
and function: a novel approach for the treatment of
parkinson's disease
INVENTOR(S): Fleckenstein, Annette E, 757 Shady Creek Place, Salt
Lake City, UT, UNITED STATES 84106
Hanson, Glen R., UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006241082 A1 20061026
APPLICATION INFO.: US 2003-528684 A1 20030919 (10)
WO 2003-US29668 20030919
20050509 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-412439P 20020919 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE
STREET, ATLANTA, GA, 30309-3915, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 5539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compositions and methods for treating Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2006:268114 USPATFULL <<LOGINID::20070503>>
TITLE: Homologous recombination in multipotent adult
progenitor cells
INVENTOR(S): Verfaillie, Catherine, St. Paul, MN, UNITED STATES
Lakshmiopathy, Uma, Minneapolis, MN, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006228798 A1 20061012
APPLICATION INFO.: US 2003-536716 A1 20031125 (10)
WO 2003-US38811 20031125
20060530 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-429631P 20021127 (60)

US 2002-429631P 20021127 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: William F Lawrence, Frommer Lawrence & Haug, 745 Fifth Avenue, New York, NY, 10151, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 2330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or ***therapeutic*** protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:248468 USPATFULL <<LOGINID::20070503>>

TITLE: Methods for the stereoselective synthesis of

substituted piperidines

INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES

Bannister, Thomas D., Northborough, MA, UNITED STATES

Cuny, Gregory D., Somerville, MA, UNITED STATES

Hauske, James R., Concord, MA, UNITED STATES

Heffernan, Michele L.R., Worcester, MA, UNITED STATES

Hoemann, Michael Z., Marlborough, MA, UNITED STATES

Kessler, Donald W., Groton, MA, UNITED STATES

Shao, Liming, Lincoln, MA, UNITED STATES

Wu, Xinhe, Shrewsbury, MA, UNITED STATES

Xie, Roger L., Natick, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006211864 A1 20060921

APPLICATION INFO.: US 2006-364506 A1 20060228 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-789414, filed on 27

Feb 2004, GRANTED, Pat. No. US 7005524 Division of Ser.

No. US 2001-12242, filed on 4 Dec 2001, GRANTED, Pat.

No. US 6703508

NUMBER DATE

PRIORITY INFORMATION: US 2000-251209P 20001204 (60)

US 2001-275600P 20010313 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 41 Drawing Page(s)

LINE COUNT: 2375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of compounds useful for treatment of numerous ailments, conditions and diseases that afflict mammals, including but not limited to addiction and pain. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the substituted piperidines using the methods of the present invention. An additional aspect of the present invention relates to enantiomerically substituted

pyrrolidines, piperidines, and azepines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:247719 USPATFULL <<LOGINID::20070503>>

TITLE: Compositions and methods for neural cell production and stabilization

INVENTOR(S): Mitalipova, Maisam, Athens, GA, UNITED STATES
Lyons, Ian, Buffalo, NY, UNITED STATES
Condie, Brian G, Athens, GA, UNITED STATES
Robins, Allan J, Athens, GA, UNITED STATES
Noggle, Scott Allen, New York, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006211111 A1 20060921
APPLICATION INFO.: US 2003-539951 A1 20031218 (10)
WO 2003-US40762 20031218
20060205 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-60434786 20021218
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Sutherland, Asbill & Brennan/Atta: Bill Warren, 999
Peachtree Street, NE, Atlanta, GA, 30309-3996, US
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 1165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for mammalian neural cell production, their stabilization and their proliferation. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a cell line or in cell culture and further contacting the cells with MEDII conditioned medium for the generation of stable mammalian neural cells from pluripotent mammalian stem cells. The invention further provides methods for the stabilization of a neural cell in culture comprising contacting the neural cell with MEDII conditioned medium. Preferably, the stabilized neural cell is a neural progenitor cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:167864 USPATFULL <<LOGINID::20070503>>

TITLE: Method for augmenting the effects of serotonin reuptake inhibitors

INVENTOR(S): Krishnan, Ranga R., Chapel Hill, NC, UNITED STATES
Caron, Marc G., Hillsborough, NC, UNITED STATES
Zhang, Xiaodong, Durham, NC, UNITED STATES
Beaulieu, Martin J., Durham, NC, UNITED STATES
Gainetdinova, Raul R., Chapel Hill, NC, UNITED STATES
Sotnikova, Tatiana D., Chapel Hill, NC, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006142375 A1 20060629
APPLICATION INFO.: US 2005-133867 A1 20050520 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2005-642869P 20050111 (60)
US 2005-642800P 20050111 (60)
US 2004-629951P 20041122 (60)
US 2004-606811P 20040902 (60)
US 2004-573265P 20040521 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH,
NC, 27627, US

NUMBER OF CLAIMS: 73

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 1362

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a subject for a serotonergic neurotransmission
dysregulation disorder, comprises administering the subject a serotonin
enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective
to treat the disorder; and concurrently administering the subject
5-hydroxytryptophan in an amount effective to enhance the activity of
the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In
preferred embodiments the disorder is depression, anxiety, or substance
abuse.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:144092 USPATFULL <<LOGINID::20070503>>

TITLE: Compositions and methods for neural differentiation of
embryonic stem cells

INVENTOR(S): Schulz, Thomas, Athens, GA, UNITED STATES
Stice, Steven L., Athens, GA, UNITED STATES
Condie, Brian G., Athens, GA, UNITED STATES
Davidson, Bruce, Adelaide, AUSTRALIA

NUMBER KIND DATE

PATENT INFORMATION: US 2006121607 A1 20060608
APPLICATION INFO.: US 2003-524157 A1 20030808 (10)
WO 2003-US24864 20030808
20050822 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-60401968 20020808
US 2003-60459090 20030331
AU 2003-300552 20030509

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SUTHERLAND ASBILL & BRENNAN LLP, 999 PEACHTREE STREET,
N.E., ATLANTA, GA, 30309, US

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 19 Drawing Page(s)

LINE COUNT: 2813

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for human neural
cell production. More particularly, the present invention provides
cellular differentiation methods employing an essentially serum free
MEDII conditioned medium for the generation of human neural cells from
pluripotent and multipotent human stem cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:130688 USPATFULL <<LOGINID::20070503>>

TITLE: Serotonin and catecholamine segment optimization
technology

INVENTOR(S): Hinz, Martin C., Duluth, MN, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006110325 A1 20060525
APPLICATION INFO.: US 2005-282965 A1 20051118 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-785158, filed
on 23 Feb 2004, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2003-449229P 20030221 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PATTERSON, THUENTE, SKAAR & CHRISTENSEN, P.A., 4800 IDS
CENTER, 80 SOUTH 8TH STREET, MINNEAPOLIS, MN,
55402-2100, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems. The methods may also include determining a urinary neurotransmitter phase response to a change in dosing of supplemental amino acid precursors of the serotonin and catecholamine neurotransmitters to optimally treat neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and/or catecholamine neurotransmitter systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2006:74727 USPATFULL <<LOGINID::20070503>>
TITLE: Piperidine-piperazine ligands for neurotransmitter
receptors
INVENTOR(S): Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, South Grafton, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2006063776 A1 20060323
APPLICATION INFO.: US 2005-215358 A1 20050829 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-808252, filed on 24
Mar 2004, GRANTED, Pat. No. US 6936614 Continuation of
Ser. No. US 2002-87609, filed on 1 Mar 2002, GRANTED,
Pat. No. US 6713479

NUMBER DATE

PRIORITY INFORMATION: US 2001-272966P 20010302 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2605

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to piperidine-piperazine compounds. A second aspect of the present invention relates to the use of the piperidine-piperazine compounds as ligands for various mammalian cellular receptors or transporters or both, including dopamine, serotonin or norepinephrine receptors or transporters, any combination of them, or all of them. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial

libraries of the piperidine-piperazine compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine receptors or transporters or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2006:74098 USPATFULL <<LOGINID::20070503>>

TITLE: Immortalized hypothalamic neuronal cell lines

INVENTOR(S): Belsham, Denise, Toronto, CANADA

Lovejoy, David, Stouffville, CANADA

NUMBER KIND DATE

PATENT INFORMATION: US 2006063143 A1 20060323

APPLICATION INFO.: US 2003-511591 A1 20030502 (10)

WO 2003-CA621 20030502

20050810 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: US 2002-376879P 20020502 (60)

US 2002-377231P 20020503 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MCCARTHY TETRAULT LLP, BOX 48, SUITE 4700,,

66WELLINGTON STREET WEST, TORONTO, ON, M5K 1E6, CA

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 22 Drawing Page(s)

LINE COUNT: 1933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method of preparing cell lines of hypothalamic origin. The method involves infecting fetal hypothalamic cells with a retroviral vector harbouring a viral oncogene, preferably SV-40 large T antigen, followed by selection and cloning. A plurality of cell lines have been prepared which express a variety of neuronal markers. The cell lines of the present invention are useful in the development of experimental models and in the treatment of disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:325928 USPATFULL <<LOGINID::20070503>>

TITLE: Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof

INVENTOR(S): Furcht, Leo T., Minneapolis, MN, UNITED STATES

Verfaillie, Catherine M., St. Paul, MN, UNITED STATES

Reyes, Morayma, Minneapolis, MN, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005283844 A1 20051222

APPLICATION INFO.: US 2005-84809 A1 20050321 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-467963, filed on 5 Jan

2004, PENDING A 371 of International Ser. No. WO

2002-US4652, filed on 14 Feb 2002

NUMBER DATE

PRIORITY INFORMATION: US 2001-343386P 20011219 (60)

US 2001-310625P 20010807 (60)

US 2001-269062P 20010215 (60)

US 2001-268786P 20010214 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BINGHAM McCUTCHEN, LLP, Three Embarcadero Center, San

Francisco, CA, 94111-4067, US

NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1-101
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 4165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for circularizing target sequences in a sample. In particular, ligation oligonucleotides are employed to selectively hybridize with the target such that the target can be ligated into a closed circular target. Rolling circle amplification can then be performed directly on the target sequence for subsequent detection and analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:299032 USPATFULL <<LOGINID::20070503>>

TITLE: Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining

INVENTOR(S): Wang, Kevin Ka-Wang, Gainesville, FL, UNITED STATES
Hayes, Ronald, Gainesville, FL, UNITED STATES
Liu, Ming Chen, Gainesville, FL, UNITED STATES
Oli, Monika, Gainesville, FL, UNITED STATES

PATENT ASSIGNEE(S): UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., GAINESVILLE, FL, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005260697 A1 20051124
APPLICATION INFO.: US 2005-106932 A1 20050415 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2004-562819P 20040415 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL, 33402-3188, US
NUMBER OF CLAIMS: 97
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 5303

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:298989 USPATFULL <<LOGINID::20070503>>

TITLE: Neural proteins as biomarkers for nervous system injury and other neural disorders

INVENTOR(S): Wang, Kevin Ka-Wang, Gainesville, FL, UNITED STATES
Hayes, Ronald, Gainesville, FL, UNITED STATES
Liu, Ming Chen, Gainesville, FL, UNITED STATES
Oli, Monika, Gainesville, FL, UNITED STATES

PATENT ASSIGNEE(S): UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., GAINESVILLE, FL, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005260654 A1 20051124
APPLICATION INFO.: US 2005-107248 A1 20050415 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2004-562944P 20040415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL,
33402-3188, US
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 4268

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2005:263227 USPATFULL <<LOGINID::20070503>>
TITLE: Compound screens relating to insulin deficiency or
insulin resistance
INVENTOR(S): Feichtinger, Richard, Gent, BELGIUM
Bogaert, Thierry, Kortrijk, BELGIUM
PATENT ASSIGNEE(S): DevGen NV, Zwijnaarde, BELGIUM, B-9052 (non-U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005229260 A1 20051013
APPLICATION INFO.: US 2002-297336 A1 20010608 (10)
WO 2001-IB1199 20010608
20030718 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: GB 2000-14009 20000608
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600
ATLANTIC AVENUE, BOSTON, MA, 02210-2211, US
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 74 Drawing Page(s)
LINE COUNT: 2772

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is concerned with use of the model organism *C. elegans* as a research tool to screen for compounds active in insulin signalling. In particular, the invention relates to improved screening methods based on release of *C. elegans* from the dauer larval state.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2005:203255 USPATFULL <<LOGINID::20070503>>
TITLE: Combination of sedative and a neurotransmitter
modulator, and methods for improving sleep quality and
treating depression
INVENTOR(S): Lalji, Karim, Sudbury, MA, UNITED STATES
Barberich, Timothy J., Concord, MA, UNITED STATES
Caron, Judy, Westwood, MA, UNITED STATES
Wessel, Thomas, Lenox, MA, UNITED STATES
PATENT ASSIGNEE(S): Sepracor, Inc., Marlborough, MA, UNITED STATES (U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005176680 A1 20050811
APPLICATION INFO.: US 2004-7795 A1 20041208 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2003-529156P 20031211 (60)

US 2004-541614P 20040204 (60)

US 2004-633213P 20041203 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110, US

NUMBER OF CLAIMS: 215

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 11615

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical ***composition*** is a GABA receptor modulating compound. The second component of the pharmaceutical ***composition*** is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT.sub.2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical ***composition*** comprises eszopiclone. In a preferred embodiment, the pharmaceutical ***composition*** comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT.sub.2A modulator or DRI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:152037 USPATFULL <<LOGINID::20070503>>

TITLE: Superoxide dismutase mimics for the treatment of optic
nerve and retinal damage

INVENTOR(S): Klimko, Peter G., Fort Worth, TX, UNITED STATES

PATENT ASSIGNEE(S): Alcon, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005130951 A1 20050616

APPLICATION INFO.: US 2004-213 A1 20041130 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2003-528830P 20031211 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Teresa J. Schultz, Alcon Research, Ltd., Mail Code
Q-148, 6201 S. Freeway, Fort Worth, TX, 76134-2099, US

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

LINE COUNT: 591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn.sup.(II) complex SOD mimics, are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:137915 USPATFULL <<LOGINID::20070503>>

TITLE: Compositions and methods for propagation of neural
progenitor cells

INVENTOR(S): Kopyov, Oleg V., Moorpark, CA, UNITED STATES

PATENT ASSIGNEE(S): Catholic Healthcare West (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005118561 A1 20050602
APPLICATION INFO.: US 2004-2933 A1 20041202 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2003-526242P 20031202 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER
DRIVE WEST, SUITE 1050, LOS ANGELES, CA, 90045, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the culturing, propagation,
cryopreservation and manipulation of neural progenitor cells (NPC) and
pluripotent stem cells (PSC) are provided. The cells exhibit rapid
doubling times and can be maintained in vitro for extended periods. Also
provided is a method of propagating neural progenitor cells, and a
method of transplanting human NPC and/or PSC to a host. The cells can be
genetically modified to express a ***therapeutic*** agent prior to
the transplanting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2005:93400 USPATFULL <<LOGINID::20070503>>
TITLE: Method of treating addiction or dependence using a
ligand for a monoamine receptor or transporter
INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
Bannister, Thomas D., Northborough, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike S., South Grafton, MA, UNITED STATES
Wang, Fengjiang, Northborough, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES
PATENT ASSIGNEE(S): Sepracor, Inc., Marlborough, MA, UNITED STATES (U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005080078 A1 20050414
APPLICATION INFO.: US 2004-771519 A1 20040204 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-607457, filed
on 26 Jun 2003, PENDING Division of Ser. No. US
2001-951130, filed on 12 Sep 2001, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2001-273530P 20010305 (60)
US 2001-298057P 20010613 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 8631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to a method of treating of
drug addiction or drug dependence in a mammal, comprising the step of
administering to a mammal in need thereof a therapeutically effective
amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In
a preferred embodiment, the method of the present invention treats
cocaine addiction or methamphetamine addiction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2005:44214 USPATFULL <<LOGINID::20070503>>

TITLE: Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419

INVENTOR(S): Stagliano, Nancy E., North Reading, MA, UNITED STATES
Healy, Aileen, Medford, MA, UNITED STATES
Acton, Susan L., Lexington, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Donoghue, Mary A., Belmont, MA, UNITED STATES
Rodrigue-Way, Amelie, Lasalle, CANADA
Tomlinson, James E., Burlingame, CA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005037946 A1 20050217
APPLICATION INFO.: US 2004-753267 A1 20040108 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2003-439683P 20030113 (60)
US 2003-445216P 20030205 (60)
US 2003-448036P 20030218 (60)
US 2003-454189P 20030312 (60)
US 2003-457541P 20030325 (60)
US 2003-466411P 20030429 (60)
US 2003-469041P 20030508 (60)
US 2003-477414P 20030610 (60)
US 2003-478560P 20030613 (60)
US 2003-489772P 20030724 (60)
US 2003-490660P 20030728 (60)
US 2003-499838P 20030903 (60)
US 2003-504786P 20030922 (60)
US 2003-505570P 20030924 (60)
US 2003-512418P 20031017 (60)
US 2003-514660P 20031027 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street,
CAMBRIDGE, MA, 02139

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 9321

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification

of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and ***therapeutic*** use of compounds as treatments of cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:321540 USPATFULL <<LOGINID::20070503>>

TITLE: Piperidine-piperazine ligands for neurotransmitter receptors

INVENTOR(S): Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, South Grafton, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004254195 A1 20041216
US 6936614 B2 20050830

APPLICATION INFO.: US 2004-808252 A1 20040324 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-87609, filed on 1 Mar 2002, GRANTED, Pat. No. US 6713479

NUMBER DATE

PRIORITY INFORMATION: US 2001-272966P 20010302 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 22

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 2657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to piperidine-piperazine compounds. A second aspect of the present invention relates to the use of the piperidine-piperazine compounds as ligands for various mammalian cellular receptors or transporters or both, including dopamine, serotonin or norepinephrine receptors or transporters, any combination of them, or all of them. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the piperidine-piperazine compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine receptors or transporters or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:300044 USPATFULL <<LOGINID::20070503>>

TITLE: Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof

INVENTOR(S): Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Heffernan, Michele L.R., Worcester, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, South Grafton, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004235913 A1 20041125
US 7087623 B2 20060808
APPLICATION INFO.: US 2004-786612 A1 20040225 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2002-123089, filed on 12 Apr
2002, GRANTED, Pat. No. US 6699866

NUMBER DATE

PRIORITY INFORMATION: US 2001-284159P 20010417 (60)
US 2001-313648P 20010820 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 106

EXEMPLARY CLAIM: 1

LINE COUNT: 5343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 23 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:300024 USPATFULL <<LOGINID::20070503>>

TITLE: Methods for the stereoselective synthesis of
substituted piperidines

INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
Bannister, Thomas D., Northborough, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Heffernan, Michele L.R., Worcester, MA, UNITED STATES
Hoemann, Michael Z., Marlborough, MA, UNITED STATES
Kessler, Donald W., Groton, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES
Wu, Xinhe, Shrewsbury, MA, UNITED STATES
Xie, Roger L., Natick, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004235893 A1 20041125
US 7005524 B2 20060228

APPLICATION INFO.: US 2004-789414 A1 20040227 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-12242, filed on 4 Dec
2001, GRANTED, Pat. No. US 6703508

NUMBER DATE

PRIORITY INFORMATION: US 2000-251209P 20001204 (60)
US 2001-275600P 20010313 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 104

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 41 Drawing Page(s)

LINE COUNT: 2533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of compounds useful for treatment of numerous ailments, conditions and diseases that afflict mammals, including but not limited to addiction and pain. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the substituted piperidines using the methods of the present invention. An additional aspect of the present invention relates to enantiomerically substituted pyrrolidines, piperidines, and azepines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 24 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:299963 USPATFULL <<LOGINID::20070503>>

TITLE: ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF
USE THEREOF

INVENTOR(S): Wu, Xinhe, Shrewsbury, MA, UNITED STATES
Aquila, Brian M., Marlborough, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES
Radeke, Heike, S. Grafor, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Xie, Roger L., Natick, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004235832 A1 20041125
US 6872716 B2 20050329

APPLICATION INFO.: US 2004-766300 A1 20040128 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-951137, filed on 12 Sep
2001, GRANTED, Pat. No. US 6703383

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 120

EXEMPLARY CLAIM: 1

LINE COUNT: 3850

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 25 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:269411 USPATFULL <<LOGINID::20070503>>

TITLE: Preparation of spermatozoa for ICSI-mediated
transgenesis and methods of using the same

INVENTOR(S): Akutsu, Hidenori, Baltimore, MD, UNITED STATES
Osada, Tomoharu, Kyoto, JAPAN
Yanagimachi, Ryuzo, Honolulu, HI, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004210955 A1 20041021
APPLICATION INFO.: US 2002-280898 A1 20021025 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-348171P 20011026 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Leslie Gladstone Restaino, Esq., Brown Raysman
Millstein Felder & Steiner LLP, 163 Madison Avenue,
P.O. Box 1989, Morristown, NJ, 07962-1989

NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1

LINE COUNT: 1245

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of preparing spermatozoa suitable for use in ICSI-mediated transgenesis, wherein the methods include the suspension of spermatozoa in a buffered medium comprising an ion-chelating agent. In a preferred embodiment of the invention, the method of preparing spermatozoa for ICSI-mediated transgenesis further comprises treatment of membrane-disrupted or demembranated spermatozoa with a disulfide reducing agent. Also provided are spermatozoa suitable for use in ICSI-mediated transgenesis, wherein the exogenous nucleic acid to be co-inserted in an unfertilized oocyte via ICSI is closely associated with the membrane-disrupted or demembranated spermatozoon. Finally, a method for obtaining a transgenic embryo is disclosed, comprising the steps of coinserting a membrane-disrupted or demembranated spermatozoon of the present invention and an exogenous nucleic acid into an unfertilized oocyte to form a transgenic fertilized oocyte, and thereafter allowing the transgenic fertilized oocyte to develop into a transgenic embryo. If so desired, the transgenic embryo may be transplanted into a surrogate mother and allowed to develop into a live transgenic offspring.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 26 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:221798 USPATFULL <<LOGINID::20070503>>

TITLE: Artificial chromosome constructs containing foreign
nucleic acid sequences

INVENTOR(S): Horsburgh, Brian, Vancouver, CANADA
Qiang, Dong, Vancouver, CANADA
Tufaro, Francis, Vancouver, CANADA
Ostrove, Jeffrey, West Vancouver, CANADA

NUMBER KIND DATE

PATENT INFORMATION: US 2004171569 A1 20040902

APPLICATION INFO.: US 2003-701152 A1 20031104 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-922271, filed on 3 Aug
2001, GRANTED, Pat. No. US 6642207 Continuation of Ser.
No. US 1998-31006, filed on 26 Feb 1998, GRANTED, Pat.
No. US 6277621

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
02110

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 983

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides artificial chromosome constructs containing foreign nucleic acid sequences, such as viral nucleic acid sequences, and methods of using these artificial chromosome constructs for therapy and recombinant virus production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 27 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2004:204026 USPATFULL <<LOGINID::20070503>>
TITLE: Weight loss induced by reduction in neuropeptide y

level
INVENTOR(S): Loftus, Thomas M., Great Falls, VA, UNITED STATES
Townsend, Craig A., Baltimore, MD, UNITED STATES
Ronnett, Gabriele, Lutherville, MD, UNITED STATES
Lane, M. Daniel, Baltimore, MD, UNITED STATES
Kuhajda, Francis P., Lutherville, MD, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004157918 A1 20040812
APPLICATION INFO.: US 2003-476513 A1 20031031 (10)
WO 2001-US5316 20010216
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY
DEPARTMENT, 1900 K STREET, N.W., SUITE 1200,
WASHINGTON, DC, 20006-1109
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted .alpha.-methylene-.beta.-carboxyl-.gamma.-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 28 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2004:185088 USPATFULL <<LOGINID::20070503>>
TITLE: 4,4-disubstituted piperidines, and methods of use

thereof
INVENTOR(S): Hoemann, Michael Z., Marlborough, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004142974 A1 20040722
APPLICATION INFO.: US 2003-722114 A1 20031125 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-12182, filed on 4 Dec
2001, GRANTED, Pat. No. US 6656953

NUMBER DATE

PRIORITY INFORMATION: US 2000-251651P 20001206 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110
NUMBER OF CLAIMS: 91
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 2966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 29 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:140277 USPATFULL <<LOGINID::20070503>>

TITLE: Multipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof

INVENTOR(S): Furcht, Leo T, Minneapolis, MN, UNITED STATES
Verfaillie, Catherine M, St Paul, MN, UNITED STATES
Reyes, Morayma, Minneapolis, MN, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004107453 A1 20040603

APPLICATION INFO.: US 2004-467963 A1 20040105 (10)

WO 2002-US4652 20020214

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: William F Lawrence, Frommer Lawrence & Haug, 745 Fifth Avenue, New York, NY, 10151

NUMBER OF CLAIMS: 101

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 4100

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the ***therapeutic*** treatment of disease are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 30 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:114713 USPATFULL <<LOGINID::20070503>>

TITLE: Methods for prevention and treatment of cancer

INVENTOR(S): Schwartz, Gary G., Winston-Salem, NC, UNITED STATES
Lokeshwar, Balakrishna L., Miami, FL, UNITED STATES
Chen, Tai C., Sudbury, MA, UNITED STATES
Whitlatch, Lyman W., Boston, MA, UNITED STATES
Holick, Michael F., Sudbury, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004087559 A1 20040506

APPLICATION INFO.: US 2003-695509 A1 20031028 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-646832, filed on 22 Sep 2000, ABANDONED A 371 of International Ser. No. WO 1999-US6491, filed on 25 Mar 1999, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ted W. Whitlock, 5323 SW 38th Avenue, Ft. Lauderdale,
FL, 33312
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1706

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for inhibiting, preventing, or treating cancer cell growth are disclosed. In one embodiment, the method comprises the step of administering to a patient an effective amount of a metabolic precursor of 1,25-dihydroxyvitamin D, or an analog or a derivative thereof, to increase levels of the metabolic precursor available to a target cell. In a preferred embodiment, the metabolic precursor is 25-hydroxyvitamin D.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 31 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2004:101836 USPATFULL <<LOGINID::20070503>>
TITLE: Ligands for monoamine receptors and transporters, and
methods of use thereof

INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
Bannister, Thomas D., Northborough, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, S. Grafton, MA, UNITED STATES
Wang, Fengjiang, Northborough, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004077706 A1 20040422
US 7132551 B2 20061107
APPLICATION INFO.: US 2003-607457 A1 20030626 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2001-951130, filed on 12 Sep
2001, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2001-273530P 20010305 (60)
US 2001-298057P 20010613 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110
NUMBER OF CLAIMS: 172
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 8278

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 32 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2004:51552 USPATFULL <<LOGINID::20070503>>
TITLE: 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods
of use thereof
INVENTOR(S): Hauske, James R., Concord, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Radeke, Heike S., South Grafton, MA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2004038983	A1	20040226
	US 7030122	B2	20060418
APPLICATION INFO.:	US 2003-401106	A1	20030327 (10)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2002-372325P	20020412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	72	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2408	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including serotonin receptors and dopamine receptors. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, and senile dementia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2004:19352 USPATFULL <<LOGINID::20070503>>
TITLE: Method for diagnosing neuronal diseases and for
treating primary hemostasis deficiency
INVENTOR(S): Walther, Deigo, Berlin, GERMANY, FEDERAL REPUBLIC OF
Bader, Michael, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2004014656	A1	20040122
	US 7049336	B2	20060523
APPLICATION INFO.:	US 2003-363474	A1	20030722 (10)
	WO 2001-DE3178		20010827

	NUMBER	DATE

PRIORITY INFORMATION:	DE 2000-10043124	20000831
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	480	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for diagnosing ***neuronal*** diseases and for treating primary hemostasis deficiency. The invention further relates to a method for suppressing the immune system, which is inter alia significant for transplantation medicine and for the treatment of allergies. The invention is used in the field of medicine and in the pharmaceutical industry. The invention is worked according to the claims. The invention is based on the discovery that ***serotonin*** is synthesized by TPH isoenzymes that are differently expressed in the neurons in the ***peripheral*** tissues. Gene targeting was used to show that an isoform, the ***peripheral*** enzyme (referred to in the following as TPH), is responsible for maintaining primary hemostasis and T-cell mediated immune responses. Another isoform, the newly identified neuron-specific TPH (referred to as nTPH) synthesizes ***serotonin*** irrespective thereof in the central nervous system. The invention further relates to the newly identified ***neuronal*** ***tryptophan*** ***hydroxylase*** (nTPH) that differs from the TPH known so far in the regulatory domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2004:103677 USPATFULL <<LOGINID::20070503>>

TITLE: Single nucleotide polymorphisms in genes

INVENTOR(S): Lander, Eric S., Cambridge, MA, United States

Cargill, Michele, Gaithersburg, MD, United States

Ireland, James S., Gaithersburg, MD, United States

Bolk, Stacey, West Roxbury, MA, United States

Daley, George Q., Weston, MA, United States

McCarthy, Jeanette J., San Diego, CA, United States

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

Whitehead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6727063 B1 20040427

APPLICATION INFO.: US 2000-657472 20000907 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-220947P 20000726 (60)

US 2000-225724P 20000816 (60)

US 1999-153357P 19990910 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Souaya, Jehanne

LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.

NUMBER OF CLAIMS: 4

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 14015

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:335405 USPATFULL <<LOGINID::20070503>>

TITLE: 4-Substituted piperidines, and methods of use thereof
INVENTOR(S): Radeke, Heike, South Grafton, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003236283 A1 20031225
APPLICATION INFO.: US 2002-317014 A1 20021211 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-339506P 20011211 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 2445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:324308 USPATFULL <<LOGINID::20070503>>
TITLE: Use of mutant herpes viruses and anticancer agents in
the treatment of cancer
INVENTOR(S): Fong, Yuman, New York, NY, UNITED STATES
Bennett, Joseph, Chicago, IL, UNITED STATES
Petrovsky, Henrik, Nidderau, GERMANY, FEDERAL REPUBLIC
OF

NUMBER KIND DATE

PATENT INFORMATION: US 2003228281 A1 20031211
APPLICATION INFO.: US 2003-358096 A1 20030203 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-872468, filed on 1 Jun
2001, ABANDONED

NUMBER DATE

PRIORITY INFORMATION: US 2000-208546P 20000601 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
02110
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of treating cancer employing mutant
herpes viruses and anticancer agents, such as chemotherapeutic drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:201433 USPATFULL <<LOGINID::20070503>>
TITLE: Method of increasing milk production
INVENTOR(S): Horseman, Nelson D., Cincinnati, OH, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003139420 A1 20030724
APPLICATION INFO.: US 2003-351474 A1 20030122 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-351134P 20020123 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FROST BROWN TODD LLC, 2200 PNC Center, 201 E. Fifth
Street, Cincinnati, OH, 45202-4182
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates generally to the use of pharmaceutical compositions to increase milk production alone or in combination with certain biological active ingredients. Specifically, the method relates to the use of pharmaceutical compositions that will act on the feedback of the intrinsic regulatory pathway in the mammalian mammary gland. The present invention provides for as a method of increasing bovine milk production as well as a method of correcting certain human lactation abnormalities. Preferably, the compounds used in the methods of the present invention are one or more active agents capable of inhibiting ***peripheral*** aromatic amino acid decarboxylase (AADC) enzymes, ***peripheral*** ***tryptophan*** ***hydroxylase*** (TPH) enzymes, ***peripheral*** ***serotonin*** (5-HT) enzymes, or a combination of enzymes thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2003:154406 USPATFULL <<LOGINID::20070503>>
TITLE: Collections of transgenic animal lines (living library)
INVENTOR(S): Serafini, Tito Andrew, San Mateo, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003106074 A1 20030605
APPLICATION INFO.: US 2002-77025 A1 20020214 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-783487, filed on 14 Feb 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 159
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 5667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides collections of transgenic animals and vectors for producing transgenic animals, which transgenic animals and vectors have a transgene comprising sequences encoding a detectable or selectable marker, the expression of which marker is under the control of regulatory sequences from an endogenous gene such that when the transgene is present in the genome of the transgenic animal, the detectable or selectable marker has the same expression pattern as the endogenous gene. Such transgenic animals can then be used to detect, isolate and/or select pure populations of cells having a particular functional characteristic. The isolated cells have uses in gene discovery, target identification and validation, genomic and proteomic analysis, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 39 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:153403 USPATFULL <<LOGINID::20070503>>

TITLE: Thiazole and other heterocyclic ligands for mammalian
dopamine, muscarinic and serotonin receptors and
transporters, and methods of use thereof

INVENTOR(S): Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Heffernan, Michele L.R., Worcester, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, Grafton, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003105071 A1 20030605
US 6699866 B2 20040302

APPLICATION INFO.: US 2002-123089 A1 20020412 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-284159P 20010417 (60)
US 2001-313648P 20010820 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 106

EXEMPLARY CLAIM: 1

LINE COUNT: 5332

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 40 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:106769 USPATFULL <<LOGINID::20070503>>

TITLE: 2-substituted piperidines that are ligands for
monoamine receptors and transporters

INVENTOR(S): Hauske, James R., Concord, MA, UNITED STATES
Aquila, Brian M., Marlborough, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003073681 A1 20030417

APPLICATION INFO.: US 2002-214383 A1 20020806 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-313934P 20010821 (60)
US 2002-353517P 20020131 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST,
155 SEAPORT BLVD, BOSTON, MA, 02110

NUMBER OF CLAIMS: 74

EXEMPLARY CLAIM: 1

LINE COUNT: 2726

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 41 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:72979 USPATFULL <<LOGINID::20070503>>

TITLE: Collections of transgenic animal lines (living library)

INVENTOR(S): Serafini, Tito Andrew, San Mateo, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003051266 A1 20030313

APPLICATION INFO.: US 2001-783487 A1 20010214 (9)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW
YORK, NY, 100362711

NUMBER OF CLAIMS: 158

EXEMPLARY CLAIM: 1

LINE COUNT: 4818

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides collections of transgenic animals and vectors for producing transgenic animals, which transgenic animals and vectors have a transgene comprising sequences encoding a detectable or selectable marker, the expression of which marker is under the control of regulatory sequences from an endogenous gene such that when the transgene is present in the genome of the transgenic animal, the detectable or selectable marker has the same expression pattern as the endogenous gene. Such transgenic animals can then be used to detect, isolate and/or select pure populations of cells having a particular functional characteristic. The isolated cells have uses in gene discovery, target identification and validation, genomic and proteomic analysis, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 42 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:72022 USPATFULL <<LOGINID::20070503>>

TITLE: Ligands for monoamine receptors and transporters, and
methods of use thereof

INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
Bannister, Thomas D., Northborough, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES

Hauske, James R., Concord, MA, UNITED STATES
Holland, Joanne M., Brookline, MA, UNITED STATES
Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, S. Grafton, MA, UNITED STATES
Wang, Fengjiang, Northborough, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003050309 A1 20030313
APPLICATION INFO.: US 2001-951130 A1 20010912 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-231667P 20000911 (60)
US 2001-273530P 20010305 (60)
US 2001-298057P 20010613 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG LLP, PATENT GROUP, 155 SEAPORT BOULEVARD,
BOSTON, MA, 02110

NUMBER OF CLAIMS: 172

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 8267

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 43 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2003:291172 USPATFULL <<LOGINID::20070503>>

TITLE: Artificial chromosome constructs containing foreign
nucleic acid sequences

INVENTOR(S): Horsburgh, Brian, Vancouver, CANADA

Qiang, Dong, Vancouver, CANADA

Tufaro, Francis, Vancouver, CANADA

Ostrove, Jeffery, West Vancouver, CANADA

PATENT ASSIGNEE(S): MediGene, Inc., San Diego, CA, United States (U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6642207 B1 20031104

APPLICATION INFO.: US 2001-922271 20010803 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-31006, filed on 26 Feb
1998, now patented, Pat. No. US 6277621

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Guzo, David

LEGAL REPRESENTATIVE: Clark & Elbing LLP

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 961

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides artificial chromosome constructs containing

foreign nucleic acid sequences, such as viral nucleic acid sequences,
and methods of using these artificial chromosome constructs for therapy
and recombinant virus production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 44 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:329484 USPATFULL <<LOGINID::20070503>>

TITLE: Viral vectors and their use in ***therapeutic***

methods

INVENTOR(S): Johnson, Paul, Vancouver, CANADA
Martuza, Robert L., Cambridge, MA, UNITED STATES
Rabkin, Samuel D., Lynn, MA, UNITED STATES
Todo, Tomoki, Belmont, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002187163 A1 20021212
APPLICATION INFO.: US 2002-107036 A1 20020327 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-279069P 20010327 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
02110

NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 988

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides viral vectors (e.g., herpes viral vectors) and
methods of using these vectors to treat disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 45 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:315232 USPATFULL <<LOGINID::20070503>>

TITLE: Methods for the stereoselective synthesis of
substituted piperidines

INVENTOR(S): Aquila, Brian M., Marlborough, MA, UNITED STATES
Bannister, Thomas D., Northborough, MA, UNITED STATES
Cuny, Gregory C., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES
Heffernan, Michele L.R., Worcester, MA, UNITED STATES
Hoemann, Michael Z., Marlborough, MA, UNITED STATES
Kessler, Donald W., Groton, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES
Wu, Xinhe, Shrewsbury, MA, UNITED STATES
Xie, Roger L., Natick, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002177721 A1 20021128
US 6703508 B2 20040309
APPLICATION INFO.: US 2001-12242 A1 20011204 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2000-251209P 20001204 (60)
US 2001-275600P 20010313 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE
SQUARE, BOSTON, MA, 02109

NUMBER OF CLAIMS: 104

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 41 Drawing Page(s)

LINE COUNT: 2542

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to methods of synthesizing substituted piperidines. A second aspect of the present invention relates to stereoselective methods of synthesizing substituted piperidines. The methods of the present invention will find use in the synthesis of compounds useful for treatment of numerous ailments, conditions and diseases that afflict mammals, including but not limited to addiction and pain. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the substituted piperidines using the methods of the present invention. An additional aspect of the present invention relates to enantiomerically substituted pyrrolidines, piperidines, and azepines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 46 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:315121 USPATFULL <<LOGINID::20070503>>

TITLE: 4,4-Disubstituted piperidines, and methods of use thereof

INVENTOR(S): Hoemann, Michael Z., Marlborough, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002177607 AI 20021128

US 6656953 B2 20031202

APPLICATION INFO.: US 2001-12182 AI 20011204 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2000-251651P 20001206 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600

NUMBER OF CLAIMS: 91

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 2998

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 47 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:258742 USPATFULL <<LOGINID::20070503>>

TITLE: Polymorphism of the human serotonin 1B receptor gene, diagnostic methods and methods of treatment based thereon

INVENTOR(S): Cigler, Tessa, Charlotte, NC, UNITED STATES
LaForge, Karl Steven, New York, NY, UNITED STATES
Kreck, Mary Jeanne, New York, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002142312 A1 20021003
APPLICATION INFO.: US 2001-855991 A1 20010515 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-204169P 20000515 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK,
NJ, 07601

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 1594

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein is a variant allele of a gene encoding a serotonin 1B receptor, A-161T, along with cloning vectors for replicating such variant alleles, and expressing vectors for expressing the variant alleles to identify alterations in the expression of serotonin 1B receptors, for identifying individuals predisposed to addictive, neurologic or psychiatric diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 48 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2002:228338 USPATFULL <<LOGINID::20070503>>

TITLE: Piperidine-piperazine ligands for neurotransmitter
receptors

INVENTOR(S): Persons, Paul E., Westborough, MA, UNITED STATES
Radeke, Heike, South Grafton, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002123499 A1 20020905

US 6713479 B2 20040330

APPLICATION INFO.: US 2002-87609 A1 20020301 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-272966P 20010302 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FOLEY HOAG LLP, PATENT GROUP, 155 SEAPORT BOULEVARD,
BOSTON, MA, 02110

NUMBER OF CLAIMS: 83

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 2808

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to piperidine-piperazine compounds. A second aspect of the present invention relates to the use of the piperidine-piperazine compounds as ligands for various mammalian cellular receptors or transporters or both, including dopamine, serotonin or norepinephrine receptors or transporters, any combination of them, or all of them. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the piperidine-piperazine compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine receptors or transporters or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 49 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2002:213415 USPATFULL <<LOGINID::20070503>>
TITLE: Cell implantation therapy for neurological diseases or disorders
INVENTOR(S): Isacson, Ole, Cambridge, MA, UNITED STATES
Kim, Kwang Soo, Lexington, MA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002114788 A1 20020822
APPLICATION INFO.: US 2001-917126 A1 20010727 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-626677, filed
on 27 Jul 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
02110
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1427

AB Disclosed herein is a method for generating functional lineage-restricted progenitors from embryonic stem cells for obtaining donor cells of specific neuronal cell-fate, in sufficient quantities for the unmet cell transplantation need for treating patients with neurodegenerative diseases or disorders.

L7 ANSWER 50 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2002:140851 USPATFULL <<LOGINID::20070503>>
TITLE: Use of mutant herpes viruses and anticancer agents in the treatment of cancer
INVENTOR(S): Fong, Yuman, New York, NY, UNITED STATES
Bennett, Joseph, Chicago, IL, UNITED STATES
Petrowsky, Henrik, Nidderau, GERMANY, FEDERAL REPUBLIC OF

NUMBER KIND DATE

PATENT INFORMATION: US 2002071832 A1 20020613
APPLICATION INFO.: US 2001-872468 A1 20010601 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-208546P 20000601 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 176 FEDERAL STREET, BOSTON, MA,
02110-2214
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods of treating cancer employing mutant herpes viruses and anticancer agents, such as chemotherapeutic drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 51 OF 59 USPATFULL on STN
ACCESSION NUMBER: 2002:126748 USPATFULL <<LOGINID::20070503>>
TITLE: Antipsychotic sulfonamide-heterocycles, and methods of use thereof
INVENTOR(S): Wu, Xinhe, Shrewsbury, MA, UNITED STATES
Aquila, Brian M., Marlborough, MA, UNITED STATES
Shao, Liming, Lincoln, MA, UNITED STATES
Radeke, Heike, S. Grafton, MA, UNITED STATES
Cuny, Gregory D., Somerville, MA, UNITED STATES
Hauske, James R., Concord, MA, UNITED STATES

Xie, Roger L., Natick, MA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002065265	A1	20020530
	US 6703383	B2	20040309
APPLICATION INFO.:	US 2001-951137	A1	20010912 (9)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2000-231607P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109	

NUMBER OF CLAIMS: 120

EXEMPLARY CLAIM: 1

LINE COUNT: 3878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 52 OF 59 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN DUPLICATE 1

ACCESSION NUMBER: 2002:575000 BIOSIS <<LOGINID::20070503>>

DOCUMENT NUMBER: PREV200200575000

TITLE: No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.

AUTHOR(S): Takahashi, Hitoshi [Reprint author]; Yoshida, Keizo; Ito, Kenichi; Sato, Kazuhiro; Kamata, Mitsuhiko; Higuchi, Hisashi; Shimizu, Tetsuo; Ito, Kunihiko; Inoue, Kazuyuki; Tezuka, Takehiko; Suzukib, Toshio; Ohkubo, Tadashi; Sugawara, Kazunobu

CORPORATE SOURCE: Department of Psychiatry, Akita University School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan
hito_takahashi@hotmail.com

SOURCE: European Neuropsychopharmacology, (October, 2002) Vol. 12, No. 5, pp. 477-481. print.
ISSN: 0924-977X.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 7 Nov 2002

Last Updated on STN: 7 Nov 2002

AB We investigated the association between serotonergic polymorphisms and incidence of nausea, which is the most frequent side-effect of selective serotonin reuptake inhibitors (SSRIs), in 66 patients treated with fluvoxamine in a protocolized-dosing method. We focused on three polymorphisms of ***serotonin*** (5-HT) ***neuronal*** systems such as 5-HT transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number of tandem repeat (VNTR) polymorphism in the second intron of the 5-HTT gene (STin2) and ***tryptophan*** ***hydroxylase*** (TPH) gene polymorphism in intron 7 (TPH-A218C), which have been reported to possess positive association with treatment response to SSRIs. In addition to this, the relationship between development of nausea and treatment response was also analyzed. Results suggested that these three polymorphisms did not affect the development of fluvoxamine-induced nausea, and that incidence of nausea was not a phenomenon that predicts the treatment response to fluvoxamine.

L7 ANSWER 53 OF 59 USPATFULL on STN

ACCESSION NUMBER: 2001:136426 USPATFULL <<LOGINID::20070503>>

TITLE: Artificial chromosome constructs containing foreign
nucleic acid sequences
INVENTOR(S): Horsburgh, Brian, Vancouver, Canada
Qiang, Dong, Vancouver, Canada
Tufaro, Francis, Vancouver, Canada
Ostrove, Jeffrey, West Vancouver, Canada
PATENT ASSIGNEE(S): MediGene, Inc., San Diego, CA, United States (U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6277621 B1 20010821
APPLICATION INFO.: US 1998-31006 19980226 (9)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Guzo, David
LEGAL REPRESENTATIVE: Clark & Elbing LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 921

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides artificial chromosome constructs containing
foreign nucleic acid sequences, such as viral nucleic acid sequences,
and methods of using these artificial chromosome constructs for therapy
and recombinant virus production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 54 OF 59 USPATFULL on STN
ACCESSION NUMBER: 1998:27764 USPATFULL <<LOGINID::20070503>>
TITLE: Tumor- or cell-specific herpes simplex virus

replication
INVENTOR(S): Martuza, Robert L., Chevy Chase, MD, United States
Rabkin, Samuel D., Bethesda, MD, United States
Miyatake, Shin-ichi, Ohtsu, Japan
PATENT ASSIGNEE(S): Georgetown University, Washington, DC, United States
(U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5728379 19980317
APPLICATION INFO.: US 1995-486147 19950607 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-264581, filed
on 23 Jun 1994, now patented, Pat. No. US 5585096
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campell, Bruce R.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 3
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2532

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for killing tumor cells in vivo entails providing replication
competent herpes simplex virus vectors to tumor cells. A replication
competent herpes simplex virus vector, with an essential herpes simplex
virus gene which is driven by a tumor-specific or cell-specific promoter
that specifically destroys tumor cells and is not neurovirulent. Also, a
method for producing an animal model, by ablating a specific cell type
in vivo, entails providing replication competent herpes simplex virus
vectors to the animal. Such a vector, with an essential herpes simplex
virus gene driven by a cell- or tissue-specific promoter, specifically
destroys the target cell type. This method of viral-mediated gene
therapy employs cell-specific viral replication, where viral replication
and associated cytotoxicity are limited to a specific cell-type by the
regulated expression of an essential immediate-early (IE) viral gene
product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 55 OF 59 USPATFULL on STN
ACCESSION NUMBER: 97:9796 USPATFULL <<LOGINID::20070503>>
TITLE: Method of treating depression using neurotrophins
INVENTOR(S): Siuciak, Judith, Tarrytown, NY, United States
PATENT ASSIGNEE(S): Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5599560 19970204
APPLICATION INFO.: US 1994-337321 19941110 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-47819, filed on 15 Apr 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Lucas, John
LEGAL REPRESENTATIVE: Kempler, Gail
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Infusion of neurotrophins, preferably brain-derived neurotrophic factor, are shown to be effective agents for use in the alleviation of symptoms of depression, as demonstrated by reduction of "despair" in the animal forced swim test. Alterations in serotonin levels brought about by neurotrophins suggest use of these factors for the treatment of other disorders caused by defects in serotonin activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 56 OF 59 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:442472 CAPLUS <<LOGINID::20070503>>
DOCUMENT NUMBER: 115:42472
TITLE: Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons
AUTHOR(S): Dawson, Valina L.; Dawson, Ted M.; Wamsley, James K.
CORPORATE SOURCE: Neuropsychiatr. Res. Inst., Fargo, ND, 58103, USA
SOURCE: Brain Research Bulletin (1990), 25(6), 903-12
CODEN: BRBUDU; ISSN: 0361-9230

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Unilateral stereotaxic injection of small amts. of the cholinotoxin, AF64A, caused minimal nonselective tissue damage and resulted in a significant loss of the presynaptic cholinergic markers [3H]hemicholinium-3 (45% redn.) and choline acetyltransferase (27% redn.). No significant change from control was obsd. in tyrosine hydroxylase or ***tryptophan*** ***hydroxylase*** activity; presynaptic ***neuronal*** markers for dopamine- and ***serotonin*** -contg. neurons, resp. The AF64A lesion resulted in a significant redn. of dopamine D2 receptors as evidenced by a decrease in [3H]sulpiride binding (42% redn.) and decrease of muscarinic non-M1 receptors as shown by a redn. in [1H]QNB binding in the presence of 100 nM pirenzepine (36% redn.). Satn. studies revealed that the change in [3H]sulpiride and [3H]QNB binding was due to a change in Bmax not Kd. Intrastratial injection of AF64A failed to alter dopamine D1 or muscarinic M1 receptors labeled with [3H]SCH23390 and [3H]pirenzepine, resp. In addn., no change in [3H]forskolin-labeled adenylate cyclase was obsd. Thus, a subpopulation of muscarinic receptors (non-M1) are presynaptic on cholinergic interneurons (hence autoreceptors), and a subpopulation of dopamine D2 receptors are postsynaptic on cholinergic interneurons. Furthermore, dopamine D1, muscarinic M1 and [3H]forskolin-labeled adenylate cyclase are not localized to striatal cholinergic interneurons.

L7 ANSWER 57 OF 59 USPATFULL on STN
ACCESSION NUMBER: 84:22987 USPATFULL <<LOGINID::20070503>>
TITLE: Method and ***composition*** for treating atherosclerosis

INVENTOR(S): Coughlin, Shaun R., 130 Bowdoin St., Apt. 1006, Boston,
MA, United States 02108

NUMBER KIND DATE

PATENT INFORMATION: US 4444778 19840424
APPLICATION INFO.: US 1982-407960 19820813 (6)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1981-297076, filed
on 27 Aug 1981, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartz, Richard A.
LEGAL REPRESENTATIVE: Crowley, Richard P.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of improving the arteriosclerotic condition in an animal having
arteriosclerosis or having a high risk of developing arteriosclerosis,
which method comprises administering an effective amount of a serotonin
regulating agent, to inhibit the biological activity of serotonin within
the blood vessels, thereby inhibiting the proliferation of smooth muscle
cells, which has been found to cause or contribute to an
arteriosclerotic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 58 OF 59 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1977:549348 CAPLUS <<LOGINID::20070503>>

DOCUMENT NUMBER: 87:149348

TITLE: Sex differentiation of neurotransmitter enzymes in
central and peripheral nervous systems

AUTHOR(S): Vaccari, A.; Brotman, S.; Cimino, J.; Timiras, P. S.

CORPORATE SOURCE: Dep. Physiol. Anat., Univ. California, Berkeley, CA,
USA

SOURCE: Brain Research (1977), 132(1), 176-85

CODEN: BRREAP; ISSN: 0006-8993

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sex-related differences in the activities of catecholamine- and
serotonin -synthesizing or -catabolizing enzymes, including
tryptophan ***hydroxylase***, DOPA decarboxylase, tyrosine
hydroxylase, catechol-O-methyltransferase, monoamine oxidase, and
5-hydroxytryptophan decarboxylase, occurred in the central and
peripheral nervous systems of rats during development; these
differences varied in magnitude and direction depending on the enzyme and
the nerve structure as well as the age of the animal studied. Female rats
generally displayed a higher enzyme activity than males in some, but not
all, brain areas. The sex-related differences were more frequent in the
adult than in the developing animal and were obsd. during prepubertal
development, indicating the involvement of both hormonal and nonhormonal
factors as determinants of sex differences.

L7 ANSWER 59 OF 59 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1975:471570 CAPLUS <<LOGINID::20070503>>

DOCUMENT NUMBER: 83:71570

TITLE: p-Chloroamphetamine. Biochemical mechanism of its
action on cerebral serotonin

AUTHOR(S): Sanders-Bush, Elaine; Sulser, F.

CORPORATE SOURCE: Sch. Med., Vanderbilt Univ., Nashville, TN, USA

SOURCE: Psychopharmacol., Sex. Disord. Drug Abuse, Proc. Symp.

Congr. Coll. Int. Neuro-Psychopharmacol., 8th (1973),

Meeting Date 1972, 607-13. Editor(s): Ban, Thomas A.

North-Holland: Amsterdam, Neth.

CODEN: 30OFAS

DOCUMENT TYPE: Conference

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Although the effects of p-chloroamphetamine-HCl (I) [25356-95-0] on
cerebral ***serotonin*** [50-67-9] and ***tryptophan***

hydroxylase [9037-21-2] are similar to those elicited by p-chlorophenylalanine Et ester [38964-54-4], I unlike p-chlorophenylalanine did not inhibit ***tryptophan***
hydroxylase in vitro in concns. up to 10⁻³M and did not decrease the rate of turnover and the biosynthesis of ***serotonin*** in ***peripheral*** tissues such as small intestine. The effects of I on levels of serotonin in brain and the activity of cerebral tryptophan hydroxylase lasted for many months, whereas the effect of p-chlorophenylalanine disappeared within 2 weeks.

=> d his

L1 QUE (TRYPTOPHAN (W) HYDROXYLASE)

L2 12571 S L1
L3 4288 S (SEROTONIN OR (SEROTONIN (W) METABOLISM))(S) L2
L4 338 S (PERIPHERAL OR NEURONAL)(S) L3
L5 4 S (COMPOSITION OR THERAPEUTIC)(S) L4
L6 61 S (COMPOSITION OR THERAPEUTIC) AND L4
L7 59 DUP REM L6 (2 DUPLICATES REMOVED)
L8 4 DUP REM L5 (0 DUPLICATES REMOVED)

=> log y